Determinants of drug delivery and transport to solid tumors.

This presentation addresses the barriers and determinants and the importance of drug-induced apoptosis in drug transport and delivery to organs and solid tumors. In particular, we examined the roles of interstitial space, drug removal by capillaries, tissue structure and tissue composition on drug distribution. Drug transport in bladder tissues is described by the distributed model which combined monodimensional Fickian diffusion and first order removal of drug by the perfusing blood. Microscopic evaluation of the spatial drug distribution in bladder, prostate and tongue indicates heterogeneous drug distribution with large and erratic concentration gradient. In general, drug distribution favors interstitial space and vasculature, with little penetration in muscles. Drug penetration into 3-dimensional solid tumors is typically 5- to 10-fold slower than in monolayer cultures. The transport of highly protein-bound drugs such as paclitaxel and doxorubicin in a solid tumor is retarded by a high tumor cell density and enhanced by drug-induced apoptosis. Accordingly, the delivery of a highly protein-bound drug to cells in a solid tumor is affected by its apoptotic effects and is therefore determined by the drug concentration and the treatment duration, i.e. treatment schedule. Under in vitro and in vivo conditions, the delivery of highly protein-bound drugs to tumor can be enhanced by using a pretreatment that induces apoptosis and reduction in cell density, and by using treatment schedules designed to take advantage of these drug-induced changes in tumor tissue composition. In conclusion, in addition to the usual processes involved in drug transport such as distribution through vascular space, transport across microvessel walls, and diffusion through interstitial space in tumor tissue, other factors including tissue structure and composition and alteration by drug-induced apoptosis are important determinants of drug distribution in organs and solid tumors.

[1]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[2]  O. Nativ,et al.  Anti‐neoplastic activity of paclitaxel on experimental superficial bladder cancer: In vivo and in vitro studies , 1997, International journal of cancer.

[3]  W D Lawrence,et al.  Paclitaxel‐induced apoptosis in MCF‐7 breast‐cancer cells , 1997, International journal of cancer.

[4]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[5]  M. Wientjes,et al.  Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.

[6]  M. Bibby,et al.  Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. , 1997, European journal of cancer.

[7]  P. Francis,et al.  Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer? , 1995, Seminars in oncology.

[8]  M. Wientjes,et al.  Pharmacodynamics of taxol in human head and neck tumors. , 1996, Cancer research.

[9]  M. Wientjes,et al.  Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  M. Wientjes,et al.  Pharmacodynamics of doxorubicin in human prostate tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Markman Intraperitoneal therapy of ovarian cancer. , 1998, Seminars in oncology.

[12]  R. Badalament,et al.  Penetration of intravesical doxorubicin in human bladders , 1996, Cancer Chemotherapy and Pharmacology.

[13]  R. Badalament,et al.  Penetration of mitomycin C in human bladder. , 1993, Cancer research.

[14]  M. Guillaume Wientjes,et al.  Bladder tissue pharmacokinetics of intravesical taxol , 1997, Cancer Chemotherapy and Pharmacology.

[15]  M. Wientjes,et al.  Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.

[16]  M. Wientjes,et al.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.

[17]  M. Wientjes,et al.  Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  R. Durand Distribution and activity of antineoplastic drugs in a tumor model. , 1989, Journal of the National Cancer Institute.

[19]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.